# HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan

> **NCT06236269** · PHASE2 · RECRUITING · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 50 (estimated)

## Conditions studied

- Breast Cancer Stage IV

## Interventions

- **DRUG:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT06236269
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2026-02-20
- **Final completion:** 2027-02-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06236269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06236269, "HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06236269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*